CyPath® Lung Sales More Than Double Year-Over-Year in Q2 for bioAffinity Technologies
BIAF sits 21% above its 52-week low of $0.693.
Summary
bioAffinity Technologies announced Q2 2026 commercial sales of its CyPath® Lung test grew over 200% year-over-year and more than 30% quarter-over-quarter. Physician offices ordering the test also increased 155% year-over-year. This strong product adoption is a critical positive development for the micro-cap company, which recently faced a 'going concern' warning and secured a $3.2 million public offering in June to extend its cash runway. Continued sales growth is essential for the company's financial stability and path to profitability.
At the time of this announcement, BIAF was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.69 to $13.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.